PT3360862T - Inibidores alcinilpiridina da prolil-hidroxilase e método de preparação e utilização médica destes - Google Patents
Inibidores alcinilpiridina da prolil-hidroxilase e método de preparação e utilização médica destesInfo
- Publication number
- PT3360862T PT3360862T PT159057215T PT15905721T PT3360862T PT 3360862 T PT3360862 T PT 3360862T PT 159057215 T PT159057215 T PT 159057215T PT 15905721 T PT15905721 T PT 15905721T PT 3360862 T PT3360862 T PT 3360862T
- Authority
- PT
- Portugal
- Prior art keywords
- preparation
- medical use
- prolyl hydroxylase
- hydroxylase inhibitor
- alkynyl pyridine
- Prior art date
Links
- -1 Alkynyl pyridine Chemical compound 0.000 title 1
- 229940078467 Prolyl hydroxylase inhibitor Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510648342.9A CN105130888A (zh) | 2015-10-09 | 2015-10-09 | 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3360862T true PT3360862T (pt) | 2020-05-27 |
Family
ID=54716523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT159057215T PT3360862T (pt) | 2015-10-09 | 2015-11-27 | Inibidores alcinilpiridina da prolil-hidroxilase e método de preparação e utilização médica destes |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10889546B2 (enExample) |
| EP (1) | EP3360862B1 (enExample) |
| JP (1) | JP6635562B2 (enExample) |
| KR (1) | KR20180063229A (enExample) |
| CN (2) | CN105130888A (enExample) |
| AU (1) | AU2015411258B2 (enExample) |
| BR (1) | BR112018005969A2 (enExample) |
| CA (1) | CA3000040A1 (enExample) |
| DK (1) | DK3360862T3 (enExample) |
| ES (1) | ES2794002T3 (enExample) |
| HR (1) | HRP20200907T1 (enExample) |
| HU (1) | HUE049409T2 (enExample) |
| LT (1) | LT3360862T (enExample) |
| MX (1) | MX379007B (enExample) |
| PL (1) | PL3360862T3 (enExample) |
| PT (1) | PT3360862T (enExample) |
| RU (1) | RU2692494C1 (enExample) |
| SI (1) | SI3360862T1 (enExample) |
| UA (1) | UA120407C2 (enExample) |
| WO (1) | WO2017059623A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105130888A (zh) | 2015-10-09 | 2015-12-09 | 中国药科大学 | 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 |
| CN107417605A (zh) * | 2017-08-02 | 2017-12-01 | 江苏艾立康药业股份有限公司 | 作用于脯氨酰羟化酶的吡啶衍生化合物 |
| CN111108098B (zh) * | 2017-10-25 | 2022-06-21 | 江苏恒瑞医药股份有限公司 | 一种炔基吡啶类脯氨酰羟化酶抑制剂的晶型及其制备方法 |
| CN110240562B (zh) * | 2018-03-08 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 一种脯氨酰羟化酶抑制剂的可药用盐、晶型及其制备方法 |
| JP2021523921A (ja) * | 2018-05-24 | 2021-09-09 | 蘇州盛迪業生物医薬有限公司Ｓｕｚｈｏｕ Ｓｕｎｃａｄｉａ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．，Ｌｔｄ． | アルキニルピリジンプロリルヒドロキシラーゼ阻害剤の製造方法 |
| CN109593084B (zh) * | 2019-01-23 | 2021-09-28 | 中国药科大学 | 脯氨酰羟化酶小分子光敏前药及其制备方法与应用 |
| BR112021017188A2 (pt) * | 2019-03-04 | 2021-11-09 | Jiangsu Hengrui Medicine Co | Composição farmacêutica de inibidor da prolil hidroxilase e método de preparação do mesmo |
| US20230295110A1 (en) * | 2020-08-14 | 2023-09-21 | Akebia Therapeutics, Inc. | Phd inhibitor compounds, compositions, and methods of use |
| CN112741834A (zh) * | 2021-02-07 | 2021-05-04 | 复旦大学附属中山医院 | HIF-1α降解抑制剂在制备酮体水平升高的冠心病药物中的应用 |
| CN116120340B (zh) * | 2021-11-15 | 2023-10-31 | 艾立康药业股份有限公司 | 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途 |
| CN116514710B (zh) * | 2022-01-21 | 2024-07-05 | 中国药科大学 | 环取代炔基吡啶甲酰甘氨酸衍生物、制备方法、药物组合物和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4410480A1 (de) * | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| MX2009000286A (es) | 2006-06-26 | 2009-03-20 | Procter & Gamble | Inhibidores de prolil hidroxilasa y metodos de uso. |
| AU2007334321B2 (en) * | 2006-12-18 | 2012-03-08 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| TW200845991A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
| TW201141839A (en) * | 2010-04-19 | 2011-12-01 | Daiichi Sankyo Co Ltd | Substituted 5-hydroxypyrimidine-4-carboxamide compounds |
| US9738604B2 (en) * | 2010-09-03 | 2017-08-22 | Duke University | Ethynylbenzene derivatives |
| CN104024227B8 (zh) * | 2011-07-22 | 2025-07-29 | 北京贝美拓新药研发有限公司 | 抑制脯氨酸羟化酶活性的化合物的晶型及其应用 |
| CN105130888A (zh) | 2015-10-09 | 2015-12-09 | 中国药科大学 | 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 |
-
2015
- 2015-10-09 CN CN201510648342.9A patent/CN105130888A/zh active Pending
- 2015-11-27 DK DK15905721.5T patent/DK3360862T3/da active
- 2015-11-27 PL PL15905721T patent/PL3360862T3/pl unknown
- 2015-11-27 MX MX2018003832A patent/MX379007B/es unknown
- 2015-11-27 JP JP2018515119A patent/JP6635562B2/ja not_active Expired - Fee Related
- 2015-11-27 PT PT159057215T patent/PT3360862T/pt unknown
- 2015-11-27 RU RU2018113258A patent/RU2692494C1/ru active
- 2015-11-27 KR KR1020187012413A patent/KR20180063229A/ko not_active Ceased
- 2015-11-27 US US15/765,387 patent/US10889546B2/en not_active Expired - Fee Related
- 2015-11-27 HU HUE15905721A patent/HUE049409T2/hu unknown
- 2015-11-27 UA UAA201804628A patent/UA120407C2/uk unknown
- 2015-11-27 LT LTEP15905721.5T patent/LT3360862T/lt unknown
- 2015-11-27 WO PCT/CN2015/095728 patent/WO2017059623A1/zh not_active Ceased
- 2015-11-27 SI SI201531228T patent/SI3360862T1/sl unknown
- 2015-11-27 CA CA3000040A patent/CA3000040A1/en not_active Abandoned
- 2015-11-27 BR BR112018005969-2A patent/BR112018005969A2/pt not_active Application Discontinuation
- 2015-11-27 HR HRP20200907TT patent/HRP20200907T1/hr unknown
- 2015-11-27 ES ES15905721T patent/ES2794002T3/es active Active
- 2015-11-27 CN CN201580079971.2A patent/CN107848976B/zh active Active
- 2015-11-27 AU AU2015411258A patent/AU2015411258B2/en not_active Ceased
- 2015-11-27 EP EP15905721.5A patent/EP3360862B1/en active Active
-
2020
- 2020-09-11 US US17/018,221 patent/US20200407319A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2692494C1 (ru) | 2019-06-25 |
| WO2017059623A1 (zh) | 2017-04-13 |
| ES2794002T3 (es) | 2020-11-17 |
| AU2015411258B2 (en) | 2020-09-17 |
| HUE049409T2 (hu) | 2020-10-28 |
| HRP20200907T1 (hr) | 2020-09-04 |
| CN107848976A (zh) | 2018-03-27 |
| PL3360862T3 (pl) | 2020-09-21 |
| CN107848976B (zh) | 2020-11-17 |
| US20200407319A1 (en) | 2020-12-31 |
| US20180305317A1 (en) | 2018-10-25 |
| SI3360862T1 (sl) | 2020-08-31 |
| KR20180063229A (ko) | 2018-06-11 |
| JP2018529690A (ja) | 2018-10-11 |
| EP3360862B1 (en) | 2020-04-22 |
| AU2015411258A1 (en) | 2018-05-10 |
| MX379007B (es) | 2025-03-11 |
| DK3360862T3 (da) | 2020-06-02 |
| HK1247613A1 (zh) | 2018-09-28 |
| JP6635562B2 (ja) | 2020-01-29 |
| US10889546B2 (en) | 2021-01-12 |
| EP3360862A4 (en) | 2018-08-15 |
| BR112018005969A2 (pt) | 2018-10-16 |
| CN105130888A (zh) | 2015-12-09 |
| UA120407C2 (uk) | 2019-11-25 |
| MX2018003832A (es) | 2018-06-18 |
| LT3360862T (lt) | 2020-07-10 |
| CA3000040A1 (en) | 2017-04-13 |
| EP3360862A1 (en) | 2018-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3546457T (pt) | Derivado de pirazolo-heteroarílico, método de preparação e a utilização médica do mesmo | |
| PL3360862T3 (pl) | Inhibitor hydroksylazy alkinylo-pirydyno-prolilowej oraz sposób jego wytwarzania i zastosowanie medyczne | |
| IL259711A (en) | Methods for the preparation of protein kinase inhibitors and their medical use | |
| PL3181560T3 (pl) | Pochodna pirydynoamidopirymidyny, sposób jej otrzymywania i zastosowanie | |
| HUE057289T2 (hu) | Oxopikolinamid-származék, annak elõállítási módszere és gyógyszerészeti felhasználása | |
| ZA202002517B (en) | Compounds and methods for reducing snca expression | |
| EP3285682A4 (en) | Intra-oral light-therapy apparatuses and methods for their use | |
| EP3381919A4 (en) | Substituted triazolopiperazine parp inhibitor, preparation method therefor, and use thereof | |
| IL266169A (en) | Compounds and methods for reducing expression of atxn3 | |
| EP3181744A4 (en) | Treatment device and treatment method | |
| GB201907083D0 (en) | 99mtc-labelled isonitrile-containing glucose derivative and preparation method and use | |
| SG11201800235RA (en) | Patient status determination device, patient status determination method and program | |
| EP3241492A4 (en) | Heart rate detection method and device | |
| ZA201705561B (en) | Kv1.3 inhibitors and their medical application | |
| ZA201701066B (en) | Pyridine derivatives and anti-mycobacterial use thereof | |
| GB2539474B (en) | Glove and treatment method | |
| IL258690A (en) | Pyridone derivatives and their use as kinase inhibitors | |
| EP3381921A4 (en) | GINKGOLIDE B DERIVATIVE AND METHOD OF PREPARING THEREOF AND USE THEREOF | |
| EP3299488A4 (en) | Carburization device and carburization method | |
| PT3263133T (pt) | Composto de piridinona e a sua utilização | |
| EP3253734A4 (en) | Glucosylceramide synthase inhibitors and therapeutic methods using the same | |
| ZA201903845B (en) | Fgfr4 inhibitor and preparation method and use thereof | |
| ZA201705676B (en) | Kv1.3 inhibitors and their medical application | |
| EP3181177B8 (fr) | Nécessaire de traitement, dispositif de mesure et utilisation associés | |
| EP3313488A4 (en) | DEVICE AND METHOD FOR OXYGEN BIOFEEDBACK |